On Wednesday, during a video update, Tesla and SpaceX CEO Elon Musk announced that his brain-computer startup, Neuralink Corp., is set to implant its device into a second human patient in a week or so.
What Happened: During the discussion, broadcasted on Musk’s social platform X, formerly Twitter, it was also revealed that Neuralink intends to have its technology in several more patients by the end of the year, with Musk stating the number could be “in the high single digits.”
The tech billionaire said that the short-term goal is to “mitigate the longer civilizational risk of AI” by creating a closer symbiosis between human intelligence and digital intelligence. He said that the idea “is to give people superpowers.”
When asked “Can a Neuralink chip repair paralysis in the long term,” Matthew MacDougall, a practicing neurosurgeon and head of Neurosurgery at Neuralink said, “We can’t do that right now. We have done preliminary work planting a second Neuralink in the spinal cord. We can restore naturalistic-looking hand and leg movements in animal models.”
He added, “Don’t hold your breath waiting for it. It’s going to be a while. We’ve got a lot of work to do.”
Subscribe to the Benzinga Tech Trends newsletter to get all the latest tech developments delivered to your inbox.
Why It Matters: In May earlier this year, the first Neuralink patient, Noland Arbaugh, passed the 100-day milestone since the chip was implanted in his brain.
However, Neuralink has also faced some challenges. Previously, it was reported that the company was aware of a malfunctioning issue with tiny wires in the brain implant for years.
Meanwhile, Neuralink is also facing competition. Last month, it was reported that neurotech startup Paradromics is preparing to conduct human trials of its brain implant, marking its entry into the competitive brain-computer interface (BCI) market where Neuralink has been dominating the headlines.
Photo by T. Schneider on Shutterstock
Check out more of Benzinga's Consumer Tech coverage by following this link.
Read Next:
Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
